Chimerix

2008

Chimerix Completes Phase I Study And Initiates A Phase II Multi-Dose Clinical Trial For CMX001    

- CMX001 is an Orally Available Broad Spectrum Antiviral Being Investigated for the Treatment of dsDNA Viruses Including Smallpox, BK Virus, CMV and Adenovirus -

RESEARCH TRIANGLE PARK, NC, January 6, 2008 – Chimerix, Inc., a biotechnology company… > Read More

Chimerix Appoints Neil Frazer, M.B., FRCA, FFPM as Chief Medical Officer    

RESEARCH TRIANGLE PARK, NC - January 3, 2008 - Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that Neil Frazer, M.B., Ch.B., FRCA, FFPM  has joined the company as Chief Medical Officer.

Prior… > Read More